%PDF-1.4
%
47 0 obj
<>
endobj
44 0 obj
<>
endobj
85 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2005-02-28T18:37:09Z
2024-03-29T03:15:09-07:00
QuarkXPressª: AdobePS 8.8.0 (301)
2024-03-29T03:15:09-07:00
application/pdf
Heather
2005-68.april
uuid:de1eed78-1dd1-11b2-0a00-e409276d7200
uuid:de1eed7a-1dd1-11b2-0a00-b80000000000
endstream
endobj
33 0 obj
<>
endobj
34 0 obj
<>
endobj
48 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 21 0 R/Type/Page>>
endobj
1 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 23 0 R/Type/Page>>
endobj
12 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 25 0 R/Type/Page>>
endobj
15 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 27 0 R/Type/Page>>
endobj
99 0 obj
[103 0 R]
endobj
100 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
13.5 787.5 585 -783 re
W n
q
0 792.03 612 -792 re
W n
BT
0 0 0 1 k
/GS1 gs
/T1_0 1 Tf
-0.00011 Tc 0.2426 Tw 10 0 0 10 54 734.8264 Tm
[(W)39.9 (ith the adoption by the )17.7 (W)79.9 (orld Health Or)17.7 (ganization of )]TJ
0.0199 Tc 0.3965 Tw 0 -1.2 TD
(the framework of the International Classification of)Tj
-0.00011 Tc 0.0843 Tw T*
(Functioning, Disability and Health \(ICF\), the medical pro-)Tj
0.0217 Tw T*
(fession accepts that its responsibility to the patients extends)Tj
0.0472 Tw T*
[(beyond control of disease activity and severity)64.8 (. Insight into)]TJ
0.14059 Tw T*
(all relevant factors \(including the socioeconomic environ-)Tj
0.12421 Tw T*
(ment\) that contribute to the comprehensive functioning of)Tj
0.0164 Tw T*
(patients will improve our care for the individual patient and)Tj
-0.00281 Tw T*
(strengthen our position in discussions on healthcare reforms)Tj
0.02499 Tw T*
(and when setting priorities for research.)Tj
/T1_1 1 Tf
0 Tw 0 -2.4 TD
(ACKNOWLEDGMENT)Tj
/T1_0 1 Tf
0.02499 Tw 8 0 0 8 54 592.8264 Tm
(I am grateful to D\216sir\216e van der Heijde for her thoughtful reading\
.)Tj
/T1_1 1 Tf
10 0 0 10 166 570.8264 Tm
(ANNELIES BOONEN,)Tj
/T1_0 1 Tf
0 Tc 6 0 0 6 268.4507 570.8264 Tm
(MD, PhD,)Tj
-0.00011 Tc 8 0 0 8 166 560.8264 Tm
(Rheumatologist, )Tj
0 -1.25 TD
[(Division of Rheumatology)64.8 (, )]TJ
T*
(University Hospital Maastricht,)Tj
T*
(and Caphri Research Institute,)Tj
0 Tc T*
[(P)110.9 (. Debyelaan 25, 6202 )54.8 (AZ Maastricht, )]TJ
-0.00011 Tc T*
(The Netherlands)Tj
/T1_2 1 Tf
-14 -2.5 Td
[(Addr)36.8 (ess r)36.8 (eprint r)36.8 (equests to Dr)110.7 (. Boonen. E-mail: aboo@sint.azm.nl)]TJ
/T1_1 1 Tf
0 Tw 10 0 0 10 54 466.8264 Tm
(REFERENCES)Tj
/T1_0 1 Tf
0.02499 Tw 8 0 0 8 61 456.8264 Tm
[(1.)-875.1 (Steinbrocker O. Prognosis for employability in the major arthritides)]TJ
1.675 -1.25 Td
(rheumatoid arthritis, osteoarthritis and gout. Pa Med 1969;72:82-5.)Tj
-1.675 -1.25 Td
[(2.)-875.1 (Mau )17.7 (W)91.9 (, Listing J, Huscher D, et al. Employment across chronic)]TJ
1.675 -1.25 Td
(inflammatory rheumatic diseases and comparison with the general)Tj
T*
(population. J Rheumatol 2005;32:721-8.)Tj
-1.675 -1.25 Td
[(3.)-875.1 (Boonen )54.8 (A, Chorus )54.8 (A, Miedema H, van der Heijde D, van der)]TJ
1.675 -1.25 Td
[(T)69.9 (empel H, van der Linden S. Employment, work disability)64.8 (, and)]TJ
T*
(work days lost in patients with ankylosing spondylitis: a cross)Tj
T*
[(sectional study of Dutch patients. )54.8 (Ann Rheum Dis 2001;60:353-8.)]TJ
31.325 44.921 Td
[(4.)-875.1 (Albers JM, Kuper HH, van Riel PL, et al. Socio-economic)]TJ
1.675 -1.25 Td
(consequences of rheumatoid arthritis in the first years of the)Tj
T*
(disease. Rheumatology Oxford 1999;38:423-30.)Tj
-1.675 -1.25 Td
[(5.)-875.1 (Chorus )54.8 (AM, Miedema HS, )17.7 (W)79.9 (evers CJ, van der Linden S. Labour)]TJ
1.675 -1.25 Td
[(force participation among patients with rheumatoid arthritis. )54.8 (Ann)]TJ
0 Tc T*
(Rheum Dis 2000;59:549-54.)Tj
-0.00011 Tc -1.675 -1.25 Td
[(6.)-875.1 (Boonen )54.8 (A, Chorus )54.8 (A, Miedema H, et al. )17.7 (W)39.8 (ithdrawal from labour)]TJ
1.675 -1.25 Td
(force due to work disability in patients with ankylosing spondylitis.)Tj
0 Tc T*
(Ann Rheum Dis 2001;60:1033-9.)Tj
-0.00011 Tc -1.675 -1.25 Td
[(7.)-875.1 (V)110.8 (erstappen SM, Bijlsma JW)91.7 (, )17.7 (V)110.8 (erkleij H, et al. Overview of work)]TJ
1.675 -1.25 Td
(disability in rheumatoid arthritis patients as observed in cross-)Tj
-0.0051 Tc T*
[(sectional and longitudinal surveys. )54.7 (Arthritis Rheum 2004;51:488-97.)]TJ
-0.00011 Tc -1.675 -1.25 Td
[(8.)-875.1 (de Croon EM, Sluiter JK, Nijssen )17.7 (TF)79.7 (, Dijkmans BA, Lankhorst GJ,)]TJ
1.675 -1.25 Td
(Frings-Dresen MH. Predictive factors of work disability in)Tj
T*
[(rheumatoid arthritis: a systematic literature review)64.9 (. )54.8 (Ann Rheum Dis)]TJ
0 Tc 0 Tw T*
(2004;63:1362-7.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(9.)-875.1 (Boonen )54.8 (A, de )17.7 (V)110.8 (et H, van der Heijde D, van der Linden S. )17.7 (W)79.9 (ork)]TJ
1.675 -1.25 Td
(status and its determinants among patients with ankylosing)Tj
T*
[(spondylitis. )54.8 (A)-220.1 (systematic literature review)64.8 (. J Rheumatol)]TJ
0 Tc 0 Tw T*
(2001;28:1056-62.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(10.)-875.1 (Dewalt DA, Berkman ND, Sheridan S, Lohr KN, Pignone MP)110.7 (.)]TJ
2.175 -1.25 Td
(Literacy and health outcomes: a systematic review of the literature.)Tj
T*
(J Gen Intern Med 2004;19:1228-39.)Tj
-2.1381 -1.25 Td
[(1)36.8 (1)-0.1 (.)-875.1 (Dadoniene J, Stropuviene S, )17.7 (V)110.8 (enalis )54.8 (A, Boonen )54.8 (A. High work)]TJ
2.1381 -1.25 Td
(disability rate among rheumatoid arthritis patients in Lithuania.)Tj
T*
(Arthritis Rheum 2004;51:433-9.)Tj
-2.175 -1.25 Td
[(12.)-875.1 (Boonen )54.8 (A, van der Heijde D, Landewe R, et al. )17.7 (W)79.9 (ork status and)]TJ
2.175 -1.25 Td
(productivity costs due to ankylosing spondylitis: comparison of)Tj
T*
[(three European countries. )54.8 (Ann Rheum Dis 2002;61:429-37.)]TJ
0 Tw -2.175 -1.25 Td
[(13.)-875.1 (www)64.9 (.OECD.or)17.7 (g)]TJ
ET
0 0 0 1 K
53.964 76.5 m
558.972 76.5 l
S
0 0 0 0 k
52.822 69.665 64.178 -15.665 re
f*
BT
0 0 0 1 k
/T1_2 1 Tf
0 Tc 8 0 0 8 53.8216 56.7343 Tm
(574)Tj
ET
0 0 0 0 k
356 69.665 203 -15.665 re
f*
BT
0 0 0 1 k
/T1_2 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 424.3613 56.7343 Tm
(The Journal of Rheumatology 2005; 32:4)Tj
ET
0 0 0 0 k
/GS0 gs
104.585 81.25 407.5 -10.833 re
f*
0.5 w
/GS1 gs
104.585 81.25 407.5 -10.833 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 g
/GS2 gs
/T1_3 8 Tf
108.828 74 Td
(Personal non-commercial use only. The Journal of Rheumatology Copyright\
\251 2005. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_4 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 29, 2024 from )Tj
ET
endstream
endobj
27 0 obj
<>stream
8;Z\7!HQ+$#iu"-j?&o0=AWKO-;J2Wp?pAk/m27XcnHjH&?#iWVu2Z-b(n0PS:!"?
hM#gB1ca>^1L9*5biGq:VKO2;%AkT
28E]GHQb"u@2WkNWj9^q&JPJ*>E.:A0!tdaW8r^tO\9a@?]&k:SmDh(29eS@/@qR6
O60UGgMs.g8F(;m1SM@OSC@3+&ke'G2s5X5+TVV
_9W+NSNO7~>
endstream
endobj
31 0 obj
[/Indexed/DeviceRGB 255 30 0 R]
endobj
30 0 obj
<>stream
J,g]g+e/h_!_gCtO=0f)$P%cIi8Zdfc5&3j_8$7g.@L`YKUJNGBP\poR=_;Dl'P(T
(7Boo^^S:71(MN]ZQX/+Cbu.lK"p74pe1T%s.DY%&\1TdJhr54.M9au6>79n6`Q:4
PbLSZTLEE(8E@'*1mg_*eTnN*;*'V3+gm-EEetX%;Bo$ur2ss*N`.-!.kG_q6GDD'
dKoL!8Ka#EV,@V!\j8ZFbp6EE<9cn=N6j0nf;(&;QU6bUD')c@\
9-d\DA=cZ0Q>gIM$$;cd2O@&a;X,Nn_aP(]I1aRc(K1^ue>
gF/(+GaKo$qneLWDrQ#;5\S(\$q'4Q,85`-8;S(=Z"WSBOV*FM)4,?B],R
endstream
endobj
50 0 obj
<>
endobj
18 0 obj
<>
endobj
54 0 obj
<>
endobj
76 0 obj
<>
endobj
90 0 obj
<>
endobj
53 0 obj
<>
endobj
61 0 obj
<>stream
HlT}PgM
*aDwWWpZΣ7R?
R#$!@ PP>jqZUTFWO[?ڙ;}<☛ q57-V*4i)ʄNqqnL7alc<|rkѯ"nk"^gg{xc;Z;.]leJVLֲإZ4QMȆ&+:Vaץ%UjVeCSRب4lBPgYZ